ASH 2021: High MCL35 Score Is Predictive of Poor Survival in Older Patients with Mantle Cell Lymphoma Treated with Bendamustine-Rituximab
In a study funded in part by LRF and led by LRF Scientific Advisory Board (SAB) and Mantle Cell Lymphoma Consortium (MCLC) member Lisa M. Rimsza, MD, of Mayo Clinic, Phoenix, researchers examined the prognostic value of the MCL35 assay in older patients (aged 65-93) with MCL who were treated with frontline bendamustine (Treanda) plus rituximab (Rituxan).
